KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Deferred Taxes (2016 - 2025)

Fulgent Genetics (FLGT) has disclosed Deferred Taxes for 8 consecutive years, with -$104000.0 as the latest value for Q4 2025.

  • Quarterly Deferred Taxes rose 71.43% to -$104000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.2 million through Dec 2025, up 67.51% year-over-year, with the annual reading at -$1.2 million for FY2025, 67.51% up from the prior year.
  • Deferred Taxes hit -$104000.0 in Q4 2025 for Fulgent Genetics, up from -$864000.0 in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $19.4 million in Q3 2023 to a low of -$5.5 million in Q1 2022.
  • Historically, Deferred Taxes has averaged -$497600.0 across 5 years, with a median of -$825000.0 in 2021.
  • Biggest five-year swings in Deferred Taxes: plummeted 599.36% in 2022 and later soared 616.52% in 2023.
  • Year by year, Deferred Taxes stood at -$1.6 million in 2021, then crashed by 107.31% to -$3.3 million in 2022, then skyrocketed by 115.0% to $502000.0 in 2023, then tumbled by 172.51% to -$364000.0 in 2024, then soared by 71.43% to -$104000.0 in 2025.
  • Business Quant data shows Deferred Taxes for FLGT at -$104000.0 in Q4 2025, -$864000.0 in Q3 2025, and -$113000.0 in Q2 2025.